Back to company

Salient Pharma ApS: Financial statements 2020

CVR: 36900709

Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -484,922 and a net result of DKK -901,594 compared with DKK -2,359,834 the year before. Equity amounted to DKK -491,947. The company had 1 employee in the financial year.

Gross Profit
-484,922 kr.
Profit/Loss
-901,594 kr.
Equity
-491,947 kr.
Total Assets
45,216 kr.
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--485 t.-902 t.-492 t.1
2019--730 t.-2.4 mio.410 t.1
2018--838 t.-710 t.2.8 mio.-
2017--1.2 mio.-971 t.-1.8 mio.-
2016--955 t.-772 t.-847 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Salient Pharma ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

Salient Pharma ApS: The 2019 annual report is outSep 28, 2020

Salient Pharma ApS has published its annual report for 2019. Gross profit came to DKK -729,822, and the net result was DKK -2,359,834.

About Salient Pharma ApS

Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity amounted to DKK -1,344,010.